NDAORALTABLET, DELAYED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUNVEYL (benzgalantamine) is an oral delayed-release tablet approved by the FDA in July 2024 as a new molecular entity from sponsor AlphaCognition. The mechanism of action, pharmacologic class, and specific indications are not yet publicly detailed in available data. This represents a novel chemical entity entering the market during its growth phase.
Growth18.7 years to LOE
As a newly approved product in growth phase with no current market data, commercial teams are likely building launch infrastructure with potential for significant headcount expansion over 12–24 months.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Started May 2026
150 enrolled
Alzheimer Disease
Career Relevance
ZUNVEYL is a newly launched product with zero current job openings but significant near-term hiring potential as AlphaCognition scales commercial infrastructure. This represents a ground-floor opportunity to build brand equity, establish market presence, and shape product strategy during critical growth years before generic competition emerges.
Brand Manager
Worked on ZUNVEYL at AlphaCognition? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.